Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 98.05
+2.15 (2.24%)
Sep 30, 2026, 4:08 PM HKT
Innovent Biologics Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 170,697 | 132,265 | 59,956 | 69,333 | 51,403 | 70,547 | |
Market Cap Growth | 6.48% | 120.60% | -13.53% | 34.88% | -27.14% | -38.71% |
Enterprise Value | 150,286 | 125,514 | 54,283 | 63,850 | 44,899 | 59,352 |
Last Close Price | 98.05 | 76.25 | 36.60 | 42.75 | 33.50 | 48.25 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 122.05 | 146.09 | - | - | - | - |
Forward PE | 46.90 | 42.67 | - | - | - | - |
PS Ratio | 9.41 | 9.11 | 5.98 | 10.14 | 9.98 | 13.46 |
PB Ratio | 7.13 | 6.14 | 4.30 | 5.02 | 4.24 | 5.56 |
P/TBV Ratio | 7.67 | 6.67 | 4.76 | 5.04 | 4.25 | 5.57 |
P/FCF Ratio | 11.43 | 12.21 | 175.32 | - | - | - |
P/OCF Ratio | 11.14 | 11.88 | 43.78 | 425.78 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.29 | 8.65 | 5.41 | 9.34 | 8.72 | 11.33 |
EV/EBITDA Ratio | 75.99 | 86.09 | 194.28 | - | - | - |
EV/EBIT Ratio | 123.92 | 153.74 | - | - | - | - |
EV/FCF Ratio | 10.06 | 11.59 | 158.73 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.14 | 0.22 | 0.29 | 0.30 | 0.24 |
Debt / EBITDA Ratio | 1.27 | 2.12 | 9.62 | - | - | - |
Debt / FCF Ratio | 0.18 | 0.29 | 8.81 | - | - | - |
Net Debt / Equity Ratio | -0.85 | -0.80 | -0.38 | -0.59 | -0.55 | -0.63 |
Net Debt / EBITDA Ratio | -9.80 | -11.77 | -19.24 | 5.70 | 2.06 | 2.57 |
Net Debt / FCF Ratio | -1.37 | -1.58 | -15.72 | 7.56 | 2.11 | 2.11 |
Asset Turnover | 0.48 | 0.44 | 0.45 | 0.33 | 0.27 | 0.30 |
Inventory Turnover | 2.46 | 2.87 | 2.52 | 1.51 | 1.00 | 1.19 |
Quick Ratio | 2.35 | 2.38 | 2.08 | 2.68 | 2.78 | 3.27 |
Current Ratio | 2.68 | 2.63 | 2.35 | 3.00 | 3.29 | 3.79 |
Return on Equity (ROE) | 7.01% | 5.01% | -0.74% | -8.84% | -20.70% | -28.56% |
Return on Assets (ROA) | 2.23% | 1.56% | -0.36% | -5.12% | -11.54% | -12.04% |
Return on Invested Capital (ROIC) | 30.16% | 11.85% | -1.86% | -31.37% | -72.59% | -95.23% |
Return on Capital Employed (ROCE) | 3.60% | 2.50% | -0.70% | -9.70% | -22.20% | -20.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.83% | 0.68% | -0.17% | -1.63% | -4.79% | -4.75% |
FCF Yield | 8.75% | 8.19% | 0.57% | -1.54% | -6.19% | -5.38% |
Buyback Yield / Dilution | -7.87% | -6.98% | -4.35% | -4.67% | -2.37% | -7.27% |